Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shuhei Nakao"'
Publikováno v:
Oncology. 100:60-64
Background: Carfilzomib is a proteasome inhibitor widely used for the treatment of multiple myeloma. However, cardiac adverse events (CAEs) are a serious side effect of carfilzomib administration. Observational studies based on systematic reviews and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e5b2b77be86cc6e77303473f03a1c97
https://doi.org/10.1159/000519687
https://doi.org/10.1159/000519687
Autor:
Tadashi Shimizu, Kenichi Asano, Masahiro Takahashi, Takashi Suda, Shuhei Nakao, Mikiko Sodeoka, Megumi Magarisawa, Naoki Terayama, Kosuke Dodo, Satoshi Yotsumoto, Takuto Tokuhiro, Erika Kuboki, Masato Tanaka, Ryu Imamura
Publikováno v:
ACS Medicinal Chemistry Letters
The indolylmaleimide (IM) derivative IM-17 shows inhibitory activity against oxidative-stress-induced necrotic cell death and cardioprotective activity in rat ischemia-reperfusion injury models. In order to develop a more potent derivative, we conduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af683b150aab9c622aec000bba003e2f
https://doi.org/10.1021/acsmedchemlett.9b00142
https://doi.org/10.1021/acsmedchemlett.9b00142
Autor:
Naoki Terayama, Koichi Fujiwara, Shuhei Nakao, Kosuke Dodo, Syusuke Egoshi, Yuki Tamura, Mikiko Sodeoka, Ayato Sato, Kana Oonuma
Publikováno v:
Chemical communications (Cambridge, England). 57(17)
γ-Linolenic acid (GLA) is reported to show tumor-selective cytotoxicity through unidentified mechanisms. Here, to assess the involvement of oxidized metabolites of GLA, we synthesized several deuterated GLAs and evaluated their metabolism and cytoto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73f4bfd2375e3f67a28ae3802699b89
https://pubmed.ncbi.nlm.nih.gov/33527102
https://pubmed.ncbi.nlm.nih.gov/33527102
Autor:
Ayako Tsuchiya, Akito Tanaka, Tadashi Shimizu, Shuhei Nakao, Tomoyuki Nishizaki, Yoshiko Kaku, Takeshi Kanno
Publikováno v:
Cancer Chemotherapy and Pharmacology
Naftopidil is clinically for treatment of benign prostate hyperplasia, and emerging evidence has pointed to its anticancer effect. To obtain the anticancer drug with the potential greater than that of naftopidil, we have newly synthesized the naftopi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f876e70ce3ef30b86ba06d31af750ca1